ReviewCancer gene therapy2022
Streptococcal bacterial components in cancer therapy.
Review in Cancer gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Vendor-specific microbiomes influence oral cancer development and its response toJournal of oral microbiology · 2026Article
- Interaction between the breast tumor microenvironment and gut microbiome.Gut microbes · 2025Review
- Oral Microbiota and Pharyngeal-Laryngeal Cancer Risk: Evidence from Mendelian Randomization in East Asian Populations.Polish journal of microbiology · 2025Article
- Dissecting Causal Relationships Between Gut Microbiota, Plasma Metabolites and Bladder Cancer: A Two-Step Mendelian Randomization Study.Health science reports · 2025Article
- Studying the Oncolytic Activity ofMicroorganisms · 2025Article
- The Oral Microbiome and Cancer.Advances in experimental medicine and biology · 2025Review
- Oncolytic bacteria: A revolutionary approach to cancer therapy.Open life sciences · 2025Review
- Two homologous sequences of Grp78 and HSP70 represent tumor antigens shared with streptococcal superantigens in eliciting an antitumor immune response: an immunoinformatic investigation.Frontiers in immunology · 2025Article
- The clinical praxis of bacteriocins as natural anti-microbial therapeutics.Archives of microbiology · 2024Review
- Effect of a Novel Food Rich in Miraculin on the Oral Microbiome of Malnourished Oncologic Patients with Dysgeusia.Cancers · 2024Article
- PA-MSHA exerts potent activity against cetuximab-resistant colorectal cancer through the miR-7-5p/Akt3/Wnt-β-catenin pathway.Translational cancer research · 2024Article
- Global compositional and functional states of the human gut microbiome in health and disease.Genome research · 2024Article
- Insights into the enigma of oral streptococci in carcinogenesis.Microbiology and molecular biology reviews : MMBR · 2024Review
- The emerging role of intra-tumoral bacteria.Journal of gastrointestinal oncology · 2024Article
- Investigating the Influence of Gut Microbiota-related Metabolites in Gastrointestinal Cancer.Current cancer drug targets · 2024Review
- Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy.Pharmaceutics · 2023Review
- Advanced Situation with Recombinant Toxins: Diversity, Production and Application Purposes.International journal of molecular sciences · 2023Review
- Recent Advances in Bacteria-Based Cancer Treatment.Cancers · 2022Review
- Emerging role of circRNAs in cancer under hypoxia.Oncology letters · 2022Review
- Oral microbiota in oropharyngeal cancers: Friend or foe?Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 4 countries.
Funding
Abstract
The incidence rate of cancer is steadily increasing all around the world, and there is an urgent need to develop novel and more effective treatment strategies. Recently, bacterial therapy has been investigated as a new approach to target cancer, and is becoming a serious option. Streptococcus strains are among the most common and well-studied virulent bacteria that cause a variety of human infections. Everyone has experienced a sore throat during their lifetime, or has been asymptomatically colonized by streptococci. The ability of Streptococcus bacteria to fight cancer was discovered more than 100 years ago, and over the years has undergone clinical trials, but the mechanism is not yet completely understood. Recently, several animal models and human clinical trials have been reported. Streptococcal strains can have an intrinsic anti-tumor activity, or can activate the host immune system to fight the tumor. Bacteria can selectively accumulate and proliferate in the hypoxic regions of solid tumors. Moreover, the bacteria can be genetically engineered to secrete toxins or enzymes that can specifically attack the tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.